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Abstract 
The National Cancer Research Institute (NCRI) is a partnership of charity and government 
research funders whose purpose is to improve health and quality of life by accelerating 
progress in cancer-related research through collaboration.  Under this umbrella, the NCRI 
Brain Tumor Clinical Studies Group is focused on improving clinical outcomes for adult 
patients with brain and central nervous system tumors, including those with brain metastasis 
from other primary sites.  This document discusses the current state of clinical brain tumor 
research in the UK and the challenges to increasing study and trial opportunities for patients.  
The clinical research priorities are defined along with a strategy to strengthen the existing 
brain tumor research network, improve access to tissue and imaging and to develop the future 
leadership for brain tumor research in the UK.  This strategy document may serve as a 
framework for other organizations and countries. 
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Introduction 
The National Cancer Research Institute (NCRI) partnership was established in 2001 
to ensure collaboration and coordination amongst cancer research funders in order to 
maximize the value and benefits of cancer research for patients and the public.  Within the 
NCRI, clinical studies groups (CSGs) were established across the major cancer sites to 
provide a forum for stakeholders to develop trials and build a strategic portfolio within their 
areas of expertise.  The original remit of the CSGs was to promote trials within the clinical 
community and also to provide constructive support for study proposals prior to submission 
to funding agencies.  More recently the remit has changed and CSGs are now expected to be 
more active in developing clinical trials in-house, with particular emphasis on interventional 
rather than observational studies. 
Since its formation the brain tumor CSG has been supported by subgroups; namely (i) 
Translational and Novel Agents, (ii) Imaging and Technology [originally separate groups 
which merged in 2012] and (iii) Supportive and Palliative Care.  These subgroups provided a 
crosscutting approach to studies across all brain tumor types.  Pediatric brain tumors fall 
under the remit of the Children's Cancer and Leukaemia CSG and due to the age eligibility 
criteria for most clinical trials, the groups function largely independently.  Over the last 
decade the number of trials on the NCRI portfolio has increased.  Neurosurgeons have 
developed and led both surgical trials such as GALA-5 1 and GALA-BIDD 2 and 
radiotherapy trials such as the ROAM trial (an international multi-center phase III trial for 
atypical meningioma) 3.  Imaging trials such as DIG PRaM-GBM have been developed and 
led by neuroradiologists and neurosurgeons.  Similar success has been achieved by 
oncologists who have taken laboratory research in DNA damage and repair biology into 
clinical trials for patients with gliomas, in the form of the PARADIGM 4 and OPARATIC 
trials 5. 
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Despite these successes, feedback from the NCRI highlighted that by their nature only 
a limited number of patients were eligible for these trials.  Targeting therapeutics in stratified 
patient cohorts is likely to exacerbate this trend, and such trends are exacerbated in less 
common cancers such as those of the brain.   There is a need to balance how we can achieve 
large-scale research involving patients across the whole of the UK and addressing all aspects 
of the cancer journey. 
The NCRI brain tumor CSG held a strategy meeting at Peterhouse College, 
Cambridge on 10-11th October 2016.  Members of the CSG and subgroups, along with 
representatives from The Brain Tumor Charity, brainstrust – the brain cancer people, Cancer 
Research UK (CRUK), the Department of Health and the National Institute of Health 
Research (NIHR) discussed the current state of brain tumor research in the UK and its future 
challenges.  This document summarizes those discussions and outlines a forward strategy for 
clinical brain tumor research in the UK. 
Burden of disease 
Approximately 9000 patients are diagnosed with a primary brain tumor each year in 
the UK, and it has been estimated that 16,000 patients suffer from brain metastasis from other 
primary sites making a total of approximately 25,000 patients affected per year in the UK 6.  
Over 102,000 people are living with a brain tumor in the UK 7 and overall, only 14% of 
patients with primary brain cancer are alive 10 years after diagnosis 6.  Although there are 
approximately 120 different types of brain tumor, the most common are gliomas, 
meningioma and metastases from extra-cranial sites such as breast, lung, kidney and skin.  
Glioblastoma is the commonest primary malignant brain tumor and the cause of the greatest 
average loss of life-years among all cancers 8 with a 2 year survival of ~25% and 5 year 
survival of ~5%.9 
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Meningiomas, meanwhile, are the commonest primary intracranial tumor overall.  
The majority can be cured by surgical resection but in a subset of patients with clinically 
aggressive meningioma the tumor may recur.  Radiotherapy may also help control these 
tumors, but there are no effective chemotherapy treatments 10.  Furthermore, cure or disease 
control does not necessarily equate to maintained quality of life and patients can often suffer 
a great deal of morbidity due to the location of the meningioma and the post treatment 
effects. 
Brain metastases affect up to 40% 11 of patients with an extracranial primary cancer, 
with an increasing incidence because of both more effective control of the primary tumor and 
greater use of brain imaging for detection of metastasis.  Surgery, stereotactic radiosurgery 
and whole brain radiotherapy continue to be the mainstay of treatment but increasingly 
therapies are targeted according to primary tumor type, including molecular subtype.  
Although some patients undoubtedly benefit from these targeted therapies, the overall 
prognosis for brain metastases is generally poor, and there are few effective treatments that 
can achieve long-term control 11,12. 
Although the incidence, care pathways and specialists involved vary according to 
primary and secondary brain tumours, all types have a major impact on patients and carers, 
since they directly affect personality, mood, speech, physical function, cognitive function, 
seizure threshold, and levels of fatigue.  As such, common themes emerge regardless of 
tumor type, for example, the primary effect of the tumor and the destructive or toxic side 
effects of the treatment (surgery, radiotherapy, and chemotherapy).  Accordingly quality of 
life is a major issue for patients living with and beyond brain cancer.  Taken together there is 
an urgent need both to improve brain tumor survival, and to improve the quality of life for 
those who do live longer and have additional morbidity from treatment. 
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Stakeholders in brain tumor research 
Patients with brain tumors can suffer from a range of neurological and quality of life 
issues that require coordinated management by a large multi-disciplinary team (MDT).  NICE 
Guidance on “improving outcomes for people with brain and other CNS tumors” 
(https://www.nice.org.uk/guidance/csg10) identifies key MDT members including 
neurosurgeons, neurologists, neuropathologists, neuroradiologists, oncologists, clinical nurse 
specialists, and Allied Health Professionals.  Many different professions and organisations 
therefore contribute to and are integral to brain tumor research.  There is strong backing 
within this community to fund and support research that will directly benefit patients, 
families and carers.  As well as Cancer Research UK (CRUK), charities specifically 
dedicated to brain cancer research, include The Brain Tumor Charity (TBTC), Brain Tumor 
Research (BTR) and brainstrust – the brain cancer people.  These charities have their own 
unique approach to brain cancer research – for example, brainstrust is a patient facing support 
charity and focuses on clinical research to improve patient and caregiver quality of life.  The 
Brain Tumor Research charity is very active at lobbying for additional government funding 
as well as fundraising for several University BTR centers of excellence.  The Brain Tumour 
Charity raises money to fund research through programme and project grants.  Despite these 
differences they all identify brain cancer as a priority area and nurturing this broad 
community of stakeholders is central to improving outcomes for patients living with brain 
tumors. 
Funding landscape: lessons from other cancers 
Two types of cancer demonstrate clearly the positive long-term correlation between 
research investment and survival rates; namely breast cancer and leukemia, which account for 
8.5% and 6.9% of all NCRI spending, respectively (www.ncri.org.uk).  Breast cancer 
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survival after 5 years is now as high as 84.3%, despite more than 50,000 new cases being 
diagnosed every year.  This remarkable success story is the product of sustained funding over 
decades, helping inform a detailed understanding of underlying tumor biology that in turn 
translates into new treatments.  
Brain tumor research is not at this advanced stage of investment or understanding and 
the cumulative research-spend on brain tumors in the UK between 2002 and 2011 was less 
than 1%, and in 2014 only 1.5% of all research-spend by the NCRI (www.ncri.org.uk).  The 
rarity of brain tumor compared to breast cancer and leukaemia is no doubt a factor that 
contributes to the lower levels of funding.  Compounding this under-funding, brain tumors 
benefit very little from advances elsewhere in “general cancer research” since brain tumors 
are very different from other cancers.  In particular the blood-brain barrier makes it more 
difficult for novel treatments, developed for systemic cancers, to reach the tumor at 
therapeutic concentrations.  Encouragingly, brain tumors have been identified as a cancer of 
unmet need and prioritized for research funding, such that CRUK would like to see a 2-3 fold 
increase in spend over the next 5 years 13.  Whilst increased investment in research does not 
come with guarantees of lowering mortality, the more we understand these complex cancers 
and invest in research infrastructure, the greater chances we will have to treat them 
effectively over the ensuing decades, adding both years to life and life to years of the affected 
patients and their families.  In addition it is essential to engage with initiatives to promote 
international collaborative working that can usefully pool resources and expertise – especially 
for the rarer subtypes of brain tumors.  Examples include the International Rare Cancers 
Initiative (IRCI)14 and the European rare cancer network (EUROCAN).15 
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Brain tumor research priorities 
A key part of developing a strategy is having a shared perspective on the priorities for 
research.  The James Lind Alliance (JLA) is funded through the NIHR and aims to address 
uncertainties about the effects of treatment.  It achieves this by bringing together patients, 
carers and clinicians to agree which clinical areas matter most and deserve priority attention.  
In 2015, the JLA Neuro-Oncology Priority Setting Partnership identified 10 clinical areas in 
brain and spinal cord tumors on which the research community should focus (table 1) 16.  
They cover all aspects of the patient journey from lifestyle factors, early diagnosis, surgery, 
radiotherapy, disease monitoring, molecular genetics, imaging, quality of life and symptom 
burden.  Most of the JLA priorities are focused on primary brain tumors, however some also 
map onto brain metastases.  Many of these map onto NHS service provision and clinical 
studies, which fall within the remit of the brain CSG.  The JLA top 10 priority questions 
provide a valuable benchmark and a useful framework for developing a research strategy, 
however the development of new clinical studies should not be restricted to these priorities 
alone.  Nevertheless the clinical importance of these research priorities are exemplified as 
follows. 
JLA priority 3: Early diagnosis of brain tumors 
Symptoms of a developing brain tumor can be non-specific, and the average general 
practitioner (GP) will see few patients who are diagnosed with a brain tumor during the 
course of their career.  In the UK in 2013, 38 % of brain tumor patients visited their GP more 
than 5 times before diagnosis 17.  Indeed 62% of all brain cancers are only discovered 
following presentations via Accident and Emergency departments, even where the same 
patient often previously presented to their GP.  This delay in diagnosis increases patient 
anxiety, and may impact on treatment options and outcome.  Timely diagnosis of brain 
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tumors remains a challenge.  The ambition is that earlier diagnosis will identify tumors at a 
smaller size which might be more amenable to complete surgical resection, in turn leading to 
a better outcome and prognosis 18. 
JLA priority 6: Molecular subtyping of tumors 
The advent of The Cancer Genome Atlas (TCGA) heralded a revolution in our 
molecular understanding of brain tumors.  In May 2016 the World Health Organization 
(WHO) published a revision of the 2007 classification of brain tumors 19 advising an 
integrated diagnosis combining molecular and genetic information of tumors with 
morphology in the classification process 20.  A precise molecular diagnosis impacts on both 
research and routine clinical decision making, facilitating clinical and translational research 
by allowing better stratification of patients based on the underlying biology of an individual’s 
tumor.  It is envisaged this will facilitate the recruitment of more homogenous populations 
into clinical trials and support a pharmacogenomics exploration of datasets to create novel 
drug repositioning opportunities.  Genome-wide screening at tumor progression/recurrence 
on tissue or liquid biopsies could facilitate patient reallocation in basket trials.  However, at 
the interface of research and clinical service delivery, one of the challenges is getting the 
appropriate test results within a clinically meaningful timeframe. 
Challenges to addressing the research priorities 
The brain tumor research community in the UK is small.  There are very few 
research-leading oncologists, neuroradiologists and neurologists, and only a modest number 
of brain tumor researchers in neurosurgery and neuropathology.  This has an impact on the 
breadth of leadership within the field, the ability to provide mentorship to aspiring 
researchers and also the number of clinical studies that can be developed and delivered on to 
the NCRI portfolio for patients to access.  Despite these challenges, in the UK all patients are 
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treated within the NHS with good contribution to national clinical data sets, such as HES 
(Hospital Episode Statistics) and the Cancer Registries. 
The current infrastructure to develop a clinical study relies heavily on individual 
university academics or research-active NHS clinicians to develop a research question into a 
short proposal for review by the CSG and relevant subgroups.  That individual will make use 
of their local network of collaborators that may include a clinical trials unit lacking 
experience of brain tumor trials.  This model is fundamentally flawed and relies heavily on a 
single motivated individual to navigate the complexities and nuances of grant applications, 
clinical trial development and protocol writing.  Failure is more often because of limited 
experience with the process, time pressures, or limited supportive infrastructure, rather than 
the lack of a good idea. 
In contrast, the pharmaceutical industry and European Organization for Research and 
Treatment of Cancer (EORTC) have access to infrastructure and expertise, but their trials will 
often only open in the UK in a few pre-selected centers - typically the same 5 or 6 units for 
each successive trial.  This inevitably leads to geographic variation in access to new trial 
drugs for patients.  In addition, the pharmaceutical industry does not prioritize brain cancer 
for new drug development, due to the challenges of delivering trials in this small but diverse 
group of patients and the issue of drug delivery across the blood-brain barrier.  The research 
community persists in this approach in order to access novel agents and derive marginal but 
meaningful gains in prognosis and outcome, but it is worthy to note that within the UK, 
medical oncologists, who tend to have dedicated research time and with whom the 
pharmaceutical industry often have most links, have not routinely been involved in brain 
tumor patient management.  This stems from the UK’s dual training of clinical oncologists in 
both systemic and radiation therapy and from the historical lack of effective systemic agents.  
However, with a growing focus on tailored, individualized therapy in all cancer groups, the 
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lack of medical oncology involvement risks missing opportunities and cross-cutting expertise 
which might present themselves via early phase units and other connections.  It is of note that 
most of the recent phase III trials in gliomas, whilst negative in terms of improving survival, 
have been from industry or the EORTC and the lead investigator has been a medical 
oncologist or neurologists 21-23. 
A strategy for brain tumor research in the UK  
The UK neuro-oncology research community is striving towards the dual goals of 
prevention or cure of brain tumors, and also that people living with and beyond a brain tumor 
should have the best quality of life possible.  At present neither of these ambitions are 
remotely met.  A strategy is needed that can encompass and harness the potential of the 
community as it works towards improving the diagnosis, treatment, prognosis, and supportive 
care of patients with brain tumors. 
1. Strengthen the existing brain tumor research network 
Following publication of the ‘Neuro-Oncology JLA Top Ten’ (table 1), the 
stakeholders and funders involved in that process developed a strategy to improve the success 
of funding applications for clinical research and clinical trials.  This strategy includes 
collaborative multi-center research, the support of Clinical Trials Units and the NIHR 
Research Design Service, and early involvement of public and patient involvement through 
the use of focused ‘Incubator Days’ (http://www.neuro-oncology.org.uk/).  Over the last 1-2 
years incubator days have been held to develop clinical trials to address epilepsy in glioma 
and the use of diet in gliomas.  As a result the existing network of clinical researchers has 
been expanded and an application has been submitted to NIHR for the SPRING trial (Seizure 
PRophylaxis IN Glioma).  Whilst this networked approach is more likely to generate 
successful clinical trials grant applications, it relies heavily on existing networks and 
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collaborators.  The neurosurgical community has established a tumor section of the SBNS to 
promote research that will enable early career surgeons to develop their ideas.  A similar 
network, the British Neurosurgical Trainee Research Collaborative (BNTRC), exists for 
trainees to develop their ideas with established links to academic neurosurgeons across the 
UK and is successfully running a study on long-term survivors with glioblastoma.  In a 
similar fashion the annual Glioma Club meeting provides a forum to foster interactions and 
networking between scientists and clinicians in the field. 
Although the British Neuro-Oncology Society (BNOS) hosts an annual conference to 
provides a forum for scientists to interact with clinicians treating brain tumor patients, it is 
poorly attended by clinical oncologists or pediatric oncologists – for whom brain tumors may 
account for only a proportion of their overall clinical practice.  As such, clinical and pediatric 
oncologists are more likely to attend either more general cancer conferences or conferences 
targeted towards pediatric malignancies respectively, for research updates.  This has 
inevitably resulted in a poor network. However in September 2016, Addenbrooke’s Hospital 
hosted a 2-day ‘bootcamp’ that brought together clinical oncologists treating brain tumor 
patients from across the UK.  A follow-up ‘CNS bootcamp’ is planned for 2017 to develop 
new clinical trials. 
2. Improve access to tissue and imaging 
The limited impact of brain cancer research worldwide on clinical outcomes for 
patients is multifactorial.  Central amongst these factors is a fundamental lack of 
understanding of brain cancer biology.  Rectifying this requires more dedicated research 
focused on brain tumors.  A key priority, then, must be to invest more in fundamental 
research that will generate novel, rational therapies based on a clearer understanding of the 
biology of these tumors.  This idea is gaining momentum in the UK but it will take many 
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years for the clinical benefit to be realized.  Parallel investment in translational research and 
infrastructure is equally important to optimize the use of currently available drugs and 
technologies and to accelerate innovation into the clinic.  Recent research has identified 
specific molecular biomarkers for brain cancer and research is urgently required to optimize 
their use to guide clinical management in the NHS.  Imaging advances in humans and pre-
clinical models can augment early phase drug development through mechanistic studies 
linked to tissue-derived data and measurement of novel agent distribution and CNS 
penetration in vivo, in addition to providing early markers of therapeutic response in both 
early and later phase studies.  Whilst the 100,000 Genome project will provide further insight 
into improving diagnosis, prognosis and personalized treatment of glioma 24, the real 
cornerstone to improving the understanding of brain tumor biology is to enable access to 
fully annotated tissue samples enriched with clinical, imaging and outcome data. 
Brain Tumor Biobank 
Although biobanking is routine for most pediatric brain tumors, only around 30% of 
adult patients are asked about gifting tumor tissue for research and patients are often not 
aware that tissue surplus to diagnostic requirements could be used for future research.  
Healthcare professionals meanwhile are uncertain about the best time and method to broach 
the subject of tissue donation, and often the discussion does not take place 7.  Furthermore, 
there is wide variation across the UK in the resources allocated for tissue biobanking.  
BRAIN UK 25 is a network of pathology laboratories and 28 of 29 UK neuroscience centers 
have made their diagnostic and autopsy archives available to researchers.  Nevertheless, more 
funding is needed to improve adult biobanking infrastructure to include frozen tissue 
samples, primary patient-derived tumor cells and liquid biopsies to create an essential 
resource to support leading research into disease biology that will have an impact on 
treatment and care.  Crucially, the biological material and molecular annotation must be 
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supplemented with verified clinical data on symptoms, treatments and outcomes.  Investment 
is needed to develop the data infrastructure and regulatory framework that will allow this to 
happen on a routine basis.  In tandem, a standard minimum imaging protocol should be 
developed and implemented so that every patient in every unit has the same MRI acquisition. 
A national biobank initiative is being developed to provide these valuable resources 
for laboratory and translational researchers.  Support is essential to maximize sample 
collection by neurosurgeons (e.g. technician support in the operating room) as well as 
cataloging in the neuropathology department.  The full complement of tissue, imaging and 
clinical data is invaluable to researchers, and access to samples will be based purely on the 
scientific quality of the application and the proposed exit strategy of the research, as assessed 
by external peer reviewers - so called scientific meritocracy. 
3. Developing capacity 
The UK clinical brain tumor research community must develop capacity in order to 
more effectively deliver clinical studies, through investment in both people and 
infrastructure.  There should be a move away from the traditional split of University 
‘academics’ and NHS (non-academic) clinicians, and instead to focus on clinical research 
teams that can effectively deliver successful grant applications and clinical trials. 
People and infrastructure 
The multi-disciplinary nature of the management of brain tumors mandates that wider 
engagement of the clinical neuro-oncology community is essential in order to identify future 
sustainable leadership.  More needs to be done to develop specialist clinical training in the 
UK through engagement with the Royal Colleges and specialist organizations.  Positive 
examples are the development of sub-specialist neurosurgical oncology by the SBNS and the 
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Association of British Neurologists Neuro-Oncology Advisory Group.  Within 
neuropathology, training in molecular pathology is to be implemented in the postgraduate 
curriculum – a positive step towards integrating molecular genetics into routine NHS 
practice, and a byproduct of which is likely to be research-active individuals.  Clinical neuro-
oncology imaging forms part of the Royal College of Radiologists core curriculum for higher 
specialist/ Neuroradiology training, although exposure to advanced quantitative imaging 
techniques is inconsistent across neuroscience centers.  The latter is being addressed through 
training days recently instituted through the British Society of Neuroradiologists (BSNR), 
however small numbers of trainees undertaking higher degrees towards clinical academic 
careers and clinical pressures in NHS posts limits research activity in imaging. 
Dedicated fellowships for senior trainees that provide a broad exposure to both 
oncology and neurology could be considered.  Efforts to promote neuro-oncology as a 
positive career for both clinical and medical oncology need to be developed and greater 
engagement by neurologists should be promoted.  Indeed many of the functional 
consequences of brain cancer and its treatment highlighted by patients are neurological (e.g. 
seizures, fatigue, language disturbance and cognitive changes) and more neurologists with an 
interest in brain cancer are required.  Education in clinical trial development and 
implementation, through fellowships or a higher degree will help ensure that future neuro-
oncology leaders will have the skills, contacts and networks to deliver well designed clinical 
trials. 
A further point to consider is that in most other developed countries, once they have 
completed surgery and radiotherapy, adult brain cancer patients are managed by medical 
oncologists/neurologists.  Brain cancer is a fundamental component of pediatric oncology 
training, but is not currently part of medical oncology training, but this group of clinicians 
could deliver future drug trials as part of a wider research community.  Indeed early-phase 
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trials in neuro-oncology are especially challenging and greater investment is required to 
develop a core number of units able to support brain cancer research with expertise on novel 
trial designs, in tandem with developing a cadre of research leading clinical and medical 
oncologists. 
Recruiting patients with brain cancer into clinical studies can be challenging therefore 
no single center will be able to deliver a suitably powered clinical trial.  Several clinical trials 
unit have experience of coordinating and delivering large multi-center brain cancer studies 
(e.g. Liverpool, Glasgow and University College London) and this network should be 
exploited and extended for future trials from the initial trial concept.  The expertise provided 
in trial methodology and health economics is invaluable for submitting competitive grants 
and ultimately delivering trials for patients onto the research portfolio. 
The Role of the Brain CSG 
The NCRI Brain CSG overarching strategic aim is to support adult brain tumor research 
through outreach and stakeholder engagement, promoting capacity development and training, 
developing data and tissue collection and prioritizing clinical research throughout the patient 
journey.  To implement the strategy the following are proposed: 
• Re-organization of the brain CSG subgroups: (i) the Glioma subgroup, (ii) the 
Meningioma, Metastases and others tumors subgroup and (iii) the Survivorship 
subgroup.  Changing the subgroup focus will facilitate a more disease-orientated 
approach and establish a clear framework for clinicians and researchers to discuss and 
develop their study and trial ideas 
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• Complete a scoping exercise of clinical, imaging and laboratory research interests 
across the UK to identify strengths, weakness and existing collaborations with a view 
to strengthening the existing networks 
• Build the profile of the group through regular engagement with the neuro-oncology 
community using existing networks.  These networks include the ABN and SBNS 
academic networks and newly formed tumor section, British Neurosurgical Trainees 
Research Collaborative (BNTRC), British Neuropathology Society (BNS), British 
Society of Neuroradiologists (BSNR), CNS Bootcamp, Glioma Club, British Neuro-
Oncology Society (BNOS) and BRAIN UK, and at annual conference meetings 
• Through engagement activities provide mentorship to early-career clinicians with 
study ideas that can be developed via the CSG subgroups and that will encourage 
individuals to join the subgroups, which will aid with succession planning when 
members reach their term on the main group 
• Map the CSG strategy to the forthcoming CRUK strategic review for brain tumor 
research key priorities 
• Ensure that the quality of research applications are internationally competitive prior to 
submission to funding organizations 
Conclusions 
Brain tumor research in the UK has increased over the last 10-15 years, but a formal, 
cohesive national strategic direction has been lacking.  In order to realize improvements in 
treatment and prognosis for patients with brain tumors we need to work collaboratively.  
Being a comparatively small academic community can be an advantage, and we should 
exploit this.  Greater emphasis needs to be placed on co-leadership of research initiatives by a 
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scientist and a clinician working together.  This would allow scientists to optimize benefit 
from material and data generated in clinical studies and allow clinicians to ensure NHS 
practice is conducted in a research-supportive manner.  National biobanking initiatives are 
essential to provide high quality clinically annotated samples, linked to national cancer 
registries that will drive translational research for new drug discovery.  Finally we must 
identify those future leaders, both clinical and laboratory based who can build on the 
proposed strategy and further develop international collaborative research networks. 
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Table 1 
James Lind Alliance Neuro-Oncology priority questions for research 
 Research Priority 
1 Do lifestyle factors (e.g. sleep, stress, diet) influence tumour growth in people 
with a brain or spinal cord tumour? 
2 What is the effect on prognosis of interval scanning to detect tumour recurrence, 
compared with scanning on symptomatic recurrence, in people with a brain 
tumour? 
3 Does earlier diagnosis improve outcomes, compared to standard diagnosis times, 
in people with a brain or spinal cord tumour? 
4 In second recurrence glioblastoma, what is the effect of further treatment on 
survival and quality of life, compared with best supportive care? 
5 Does earlier referral to specialist palliative care services at diagnosis improve 
quality of life and survival in people with a brain or spinal cord tumours? 
6 Do molecular subtyping techniques improve treatment selection, prediction and 
prognostication in people with a brain or spinal cord tumour? 
7 What are the long-term physical and cognitive effects of surgery and/or 
radiotherapy when treating people with a brain or spinal cord tumour? 
8 What is the effect of interventions to help carers cope with changes that occur in 
people with a brain or spinal cord tumour, compared with standard care? 
9 What is the effect of additional strategies for managing fatigue, compared with 
standard care, in people with a brain or spinal cord tumour? 
10 What is the effect of extent of resection on survival in people with a suspected 
glioma of the brain or spinal cord? 
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